| Document |
Document Title |
|
WO/2024/050061A3 |
The present disclosure is directed to substituted Pyrazole and Imidazole derivatives of compounds that are antagonists and/or modulators of orexin and kappa-opioid receptors, and which are useful in the treatment or prevention of neurolo...
|
|
WO/2024/080736A1 |
The present invention provides a feature related to a cored tablet combination preparation comprising clopidogrel or a pharmaceutically acceptable salt thereof and ilaprazole as active ingredients. The cored tablet combination preparatio...
|
|
WO/2024/081861A1 |
Disclosed herein are 2 novel long non-coding RNAs (lncRNAs), TROLL-2C and TROLL-3A. It is shown herein that lncRNAs TROLL-2C and TROLL-3A are suitable targets for cancer therapies and can be used to make prognostic determinations about a...
|
|
WO/2024/079664A1 |
The disclosure provides compositions including a human milk oligosaccharide (HMO), as well as methods of using the same for reducing inflammation of the skin, treating or preventing psoriasis, acne, rosacea, eczema, erythema, UV radiatio...
|
|
WO/2024/079753A1 |
The present invention discloses to a lyophilized composition suitable for parenteral administration. More particularly, the present invention discloses to an injectable lyophilised pharmaceutical composition comprising a β-lactam antibi...
|
|
WO/2024/079472A1 |
A prebiotic oligosaccharide composition for use in reducing branched short chain fatty acids (BSCFAs). The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt% ...
|
|
WO/2024/081345A1 |
Novel PI3K inhibitors of the general formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, formula (1), wherein R1 to...
|
|
WO/2024/077506A1 |
Atovaquone is used for treating and preventing acute and chronic inflammatory diseases in mammals, including mast cell-mediated inflammatory diseases.
|
|
WO/2024/080792A1 |
Provided are a compound, selected from compounds of Formula 1, enantiomers, diastereomers, solvates and hydrates thereof, and pharmaceutically acceptable salts thereof, methods of preparing the same, and use thereof.
|
|
WO/2024/081929A1 |
Technologies for the prevention and/or treatment of pathogenic or microbial infections. Compositions relate to compositions, vaccines and methods comprising an immunogenic multiple antigen presenting system (MAPS), where two or more biot...
|
|
WO/2024/079076A1 |
dsRNAi oligonucleotides can be used in methods for the treatment of the advanced fibrotic and/or cirrhotic stages of NASH.
|
|
WO/2024/044649A3 |
Described herein, inter alia, are GTPase inhibitors and uses thereof.
|
|
WO/2024/079677A1 |
The present invention discloses a compound of structural formula (I) or a pharmaceutically acceptable salt thereof; in which X is selected from group comprising of unsubstituted or substituted 1. linear aliphatic alkyl carboxylic acids, ...
|
|
WO/2024/078555A1 |
The present invention relates to the field of drugs, and specifically, the present invention relates to a pyrimidopyridine compound, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a compo...
|
|
WO/2024/059878A3 |
TERT plays a crucial role in cancer formation, ensuring chromosomal stability by maintaining telomere length and allowing cells to avoid senescence. Development of telomerase inhibitors has been challenging and thus far there are no clin...
|
|
WO/2024/044774A3 |
Provided herein is a neoadjuvant therapy and/or adjuvant therapy for the treatment of uveal melanoma, inter alia, ocular tumors in uveal melanoma to reduce the incidence of metastasis and/or enucleation and/or preserving eye function.
|
|
WO/2024/079071A1 |
dsRNAi oligonucleotides can be used in methods for the treatment of NASH, preferably the advanced fibrotic and/or cirrhotic stages thereof, using dosage regimens comprising a loading phase followed by a maintenance phase.
|
|
WO/2024/078568A1 |
Provided in the present invention are a treatment method for treating cancer patients accompanied by pain by using a combination of an AKR1C3 activated anticancer prodrug compound and an analgesic drug, a pharmaceutical use, a drug combi...
|
|
WO/2024/081925A1 |
Provided herein are lipid nanoparticle complex with nanoparticles cloaked in monocyte plasma membrane for effective delivery of drugs. Also provided herein are drug loaded lipid nanoparticle complex for inhibition of YAP/TAZ pathway and ...
|
|
WO/2024/078515A1 |
The present invention relates to an ophthalmic pharmaceutical composition containing levamisole, a preparation method therefor, and a use thereof, and in particular relates to an ophthalmic preparation. The ophthalmic preparation compris...
|
|
WO/2024/081351A1 |
Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
|
|
WO/2024/081311A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition or degradation of Cbl-b, and the treatment of Cbl-b-mediated disorders. Formula (I)
|
|
WO/2024/078620A1 |
A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...
|
|
WO/2024/081385A1 |
Disclosed herein are compounds that are Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using ...
|
|
WO/2024/080788A1 |
The present invention relates to a novel tricycle derivative compound and uses thereof, more specifically to a novel tricycle derivative compound having inhibitory activity for methionine adenosyltransferase 2A (MAT2A) and uses thereof.
|
|
WO/2024/078649A1 |
The invention relates to furopyridine compounds of formula (I) for use in the treatment of FLT3-related, DDR-related and MAP4K-related diseases.
|
|
WO/2024/078283A1 |
The present invention belongs to the field of medicine, and specifically relates to crisaborole or a pharmaceutically acceptable salt aqueous solution composition thereof, comprising an amino acid or a derivative thereof. The crisaborole...
|
|
WO/2024/080844A1 |
The present disclosure relates to a novel pyrimidine derivative, a solvate or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including any of the foregoing as an active ingredient, t...
|
|
WO/2024/081688A2 |
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
|
|
WO/2024/078592A1 |
The present invention relates to a compound targeting fibroblast activation protein (FAP) as shown in formula (X) and a use thereof, and further relates to a pharmaceutical composition containing the compound and a use. The compound or t...
|
|
WO/2024/081447A1 |
Disclosed herein are methods of treating treatment-resistant lung cancer, such as non-small cell lung cancer, using EGFR inhibitors.
|
|
WO/2024/080354A1 |
The present invention provides a compound, or an N-oxide thereof, which has an excellent controlling effect with respect to harmful arthropods and which is represented by formula (I) (in the formula: Q denotes a group represented by form...
|
|
WO/2024/080355A1 |
The present invention provides a compound represented by formula (I) [wherein, Q represented by the formula below (wherein # represents a binding site with a sulfur atom, and ● represents a binding site with Het) represents, inter alia...
|
|
WO/2024/080777A1 |
The present invention provides a pharmaceutical composition advantageously useful for preventing or treating nephritis.
|
|
WO/2024/081864A1 |
The invention relates to compounds and pharmaceutical compositions capable of treating and/or restoring or increasing sensitivity of NT5C2-mutant leukemia cells to chemotherapy, as well as methods of using thereof for treating and/or res...
|
|
WO/2024/078483A1 |
The present invention belongs to the technical field of biological medicines. Disclosed is a novel ceramide which has a structure represented as formula I. Further disclosed in the present invention are a preparation method for and the u...
|
|
WO/2024/081352A2 |
The present disclosure provides third-generation self-inactivating (SIN) lentiviral vectors comprising a nucleic acid sequence encoding MyoVIIa isoform 1 for treatment of Usher IB syndrome in a subject in need thereof. In some embodiment...
|
|
WO/2024/081383A2 |
Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such g...
|
|
WO/2024/078553A1 |
Provided is a method for preventing, relieving, alleviating and/or treating pneumoconiosis, the method comprising administering to an individual in need thereof an effective amount of the compound of formula (I) or a pharmaceutically acc...
|
|
WO/2024/080364A1 |
Provided is an antifibrotic agent comprising a copolymer having a constituent unit (a) containing an N-acetylglucosamine group and a constituent unit (b) containing a structure represented by general formula (b) (excluding a constituent ...
|
|
WO/2024/079364A1 |
The present invention relates to cladribine or a pharmaceutically acceptable salt, hydrate, solvate thereof for use in preventing and/or treating a bacterial infection, wherein said bacterial infection is caused by a gram negative bacter...
|
|
WO/2024/079542A1 |
The present invention relates to stable liquid oral pharmaceutical formulations of cannabidiol (CBD) and also discloses methods of producing stabilized formulations of cannabidiol using cannabidiol from a synthetic source. The stable for...
|
|
WO/2024/078312A1 |
The use of a sulfonated polysaccharide. The sulfonated polysaccharide has a strong capability of inhibiting SARS-CoV-2 from infecting host cells, and therefore can be used for preparing drugs for treating and/or preventing corona virus d...
|
|
WO/2024/044375A3 |
The invention provides a compound of formula I: (I) or a salt thereof, wherein R1-R4 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antiviral...
|
|
WO/2024/081763A1 |
The present invention relates to the treatment of a sporadic ALS patient with oral fasudil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using t...
|
|
WO/2024/054622A3 |
The invention provides compounds that are useful for treatment of conditions associated with aberrant activity of voltage gated sodium channel Navl.8, and methods of treating a subject with those compounds for conditions such as pain, it...
|
|
WO/2024/055006A3 |
Disclosed herein, inter alia, are methods of treating pain by administering compositions that include at least one purified free amino acid, at least one purified fatty acid, and a purified fatty acid amide, related compositions, and kit...
|
|
WO/2024/078387A1 |
A substituted 3-fluorobenzenepropanoate compound represented by formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate (such as a hydrate) thereof, a clathrate thereof, a racemate thereof, a co-crys...
|
|
WO/2024/078449A1 |
The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.
|
|
WO/2024/080780A1 |
The present invention relates to an indazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing, treating, or ameliorating cancer, comprising, as an active ingredient, the derivative or a pharmaceu...
|
